Language selection

Government of Canada / Gouvernement du Canada

Search

Updated guidance to protect infants and children from respiratory syncytial virus (RSV) disease : use of monoclonal antibodies (nirsevimab and clesrovimab) and the RSVpreF vaccine.: HP40-402/2026E-PDF ; HP40-402/2026-1E-PDF

Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.960574&sl=0

Publication information
Department/Agency
  • Public Health Agency of Canada, issuing body.
  • Canada. National Advisory Committee on Immunization, issuing body.
TitleUpdated guidance to protect infants and children from respiratory syncytial virus (RSV) disease : use of monoclonal antibodies (nirsevimab and clesrovimab) and the RSVpreF vaccine.
Publication typeMonograph
Language[English]
Other language editions[French]
FormatDigital text
Electronic document
Note(s)
  • Issued also in French under title: Recommandations mises à jour pour protéger les nourrissons et les enfants contre la maladie causée par le virus respiratoire syncytial (VRS) : utilisation d'anticorps monoclonaux (nirsévimab et clesrovimab) et du vaccin RSVpreF.
  • "An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI)"--Cover.
  • "Pub.: 250479 ."
  • "Pub.: 250481."
  • Replaced with corrected version at the publisher's request (April 15, 2026).
  • Includes bibliographical references (pages 47-54).
Publishing information
  • Ottawa, ON : Public Health Agency of Canada = Agence de la santé publique du Canada, April 2026.
  • ©2026
Description1 online resource (54 pages) + summary (5 pages)
ISBN9780660987712 9780660987705
Catalogue number
  • HP40-402/2026E-PDF
  • HP40-402/2026-1E-PDF
Subject terms
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.

Page details

Report a problem or mistake on this page
Date modified: